JD Bioscience

Heart disease, a leading cause of death globally, can be categorized into ischemic heart disease, cardiomyopathy, and myocarditis.

Different types of medication are available to treat heart disease, for example, cholesterol-lowering medications, beta-blockers, nitroglycerin, and calcium channel blockers. However, none of these can rescue the function of cardiomyocytes once heart failure is in progression.

Ischemic heart disease is involved in the reduction of blood flow due to the accumulation of fatty deposits in the coronary arteries. Cardiomyopathy, including hypertrophic or dilated cardiomyopathy, is a disease of the heart muscle that can occur due to various risk factors. Finally, myocarditis is characterized by the inflammation of the heart muscle, which often occurs due to a viral infection. All of these can ultimately lead to fatal heart failure.

JDB is developing a novel drug candidate for heart disease that can rescue heart function at a cellular level, and can eventually help improving heart function.